Fundraising FoxPureTech Health — 2019 Investments
1 investments dated 2019 · listed companies and verified rows first · show all
Karunatxkarunatx.comApr 2019Acquired
Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.
Co-investorsARCH Venture PartnersPivotal Life SciencesSofinnova VenturesAlexandriaWellcome Trust
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.